Skip to content

Price / book at other companies

Merck & Co. logo
Merck & Co.MRK
6.5×+1.8×
Zoetis logo
ZoetisZTS
15.4×-0.4×
Elanco Animal Health Inc. logo
Elanco Animal Health Inc.ELAN
1.8×+1.0×
Neogen logo
NeogenNEOG
1.2×+0.3×
Balchem logo
BalchemBCPC
4.2×-0.2×
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
23×+13.5×

Other financials

Income statement

See full
Revenue$383.5M+10.3%
Gross profit$125.7M+20.2%
Operating income$44.7M+33.2%
Net income$24.0M+15.1%
EPS (diluted)$0.59+15.7%

Balance sheet

See full
Cash & equivalents$54.9M-9.0%
Total debt$32.3M+27.8%
Total equity$361.8M+36.0%
Total assets$1.4B+9.7%

Cash flow

See full
Operating cash flow$16.2M-62.4%
CapEx$15.3M+97.7%
Free cash flow$890.0K-97.5%

Valuation

See full
Market cap$1.27B+31.4%
Enterprise value$1.25B+33.9%
P/E13.4×-17.1×
P/S0.9×0.0×

Profitability

See full
Gross margin32.5%+0.9pp
Operating margin12%+4.0pp
Net margin6.3%+3.7pp
FCF margin0.9%-3.3pp

Returns & leverage

See full
Return on equity30.3%+18.5pp
Debt / equity0.1×0.0×
Current ratio3.2×+0.3×

Where this comes from

Calculated from Phibro Animal Health’s reported figures.

Based on the most recent quarter.

The official record: Phibro Animal Health’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Phibro Animal Health's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Phibro Animal Health's price / book?
Phibro Animal Health (PAHC) reported price / book of 6.2× in Q1 2026.
How has Phibro Animal Health's price / book changed year-over-year?
Phibro Animal Health's price / book increased by 90.5% year-over-year, from 3.3× to 6.2×.
What is the long-term trend for Phibro Animal Health's price / book?
Over 4 years (2021 to 2025), Phibro Animal Health's price / book has grown at a -8.0% compound annual growth rate (CAGR), from 4.9× to 3.5×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.